Citation

Lebwohl MG, Blauvelt A, Menter A, Papp KA, Guenthner S, Pillai R, Israel RJ, Jacobson A. Am. J. Clin. Dermatol. 2019; 20(6): 863-871.

Copyright

(Copyright © 2019, Springer International)

DOI

10.1007/s40257-019-00466-2

PMID

31493163

PMCID

PMC6872506

Abstract

BACKGROUND: Chronic inflammatory diseases such as psoriasis require treatment options that maintain efficacy and tolerability during extended treatment.
OBJECTIVE: The aim of the study was to assess the long-term efficacy and safety of brodalumab, a fully human anti-interleukin-17 receptor A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis.
METHODS: Patients who completed a 12-week, phase II, dose-ranging clinical trial received brodalumab 210 mg every 2 weeks in an open-label extension study. Efficacy was assessed by static physician's global assessment (sPGA) and psoriasis area and severity index (PASI). Quality of life, assessed by dermatology life quality index (DLQI), and safety were also evaluated.
RESULTS: Overall, 181 patients received brodalumab for a median of 264 weeks. Brodalumab treatment resulted in rapid improvements in sPGA, PASI, and DLQI that were maintained through week 264. Achieving PASI 90 to < 100 or PASI 100 at weeks 12, 240, and 264 was associated with greater likelihood for DLQI 0 or 1 compared with achieving PASI 75 to < 90. Over 5 years, one adverse event of suicidal ideation was reported, no suicides occurred, and no new safety signals emerged.
CONCLUSIONS: Brodalumab demonstrated skin clearance and improved quality of life, with an acceptable safety profile, throughout 5 years of treatment. CLINICALTRIALS.
GOV IDENTIFIER: NCT01101100.

Language: en

Keywords

Humans; Adult; Aged; Female; Male; Middle Aged; Adolescent; Severity of Illness Index; Young Adult; Time Factors; Treatment Outcome; Suicidal Ideation; Quality of Life; Psoriasis; Dermatologic Agents; Skin; Antibodies, Monoclonal, Humanized; Long-Term Care; Patient Reported Outcome Measures; Interleukin-17